Gang Li

Senior Director, In-Vivo Pharmacology, Pioneering Medicines

Gang Li joined Flagship Pioneering in 2022 as Senior Director, Head of In Vivo Pharmacology for Pioneering Medicines. He is responsible for leading the In-Vivo team and working with cross-functional teams to support Pioneering Medicines’ programs across different therapeutic areas.

Gang has 12 years of industry experience leading research programs across different therapeutic areas including cardio-pulmonary-renal diseases, obesity, diabetes, and various fibrotic diseases. Prior to joining Pioneering Medicines, he was director of preclinical pharmacology at Acceleron Pharma. During his seven years at Acceleron, he built and led a research team to support several drug discovery programs from early discovery to clinical development including the Sotatercept program which is currently in Phase 3 for PAH and Phase 2 for PH-HFpEF and the ACE1334 program which is currently in Phase 1b/2 for systemic sclerosis. In addition, he was the preclinical lead for several regulatory submissions and managed multiple academic and CRO collaborations to support Acceleron’s R&D portfolio. Previously, he was the research project leader at Genzyme, Sanofi, responsible for target identification, lead validation, and preclinical PoC for several fibrotic and tissue regeneration programs.

Gang received his Ph.D. in Pathology from Wayne State University School of Medicine and completed his postdoctoral training at Columbia University Medical Center.